INMED PHARMACEUTICALS INC. Deferred Offering Costs
INMED PHARMACEUTICALS INC. (INM) had Deferred Offering Costs of $25.00 thousand as of 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-07-02
- 2025-03-31: Deferred Offering Costs $25.00K.
- 2024-06-30: Deferred Offering Costs $106.30K.
- 2021-06-30: Deferred Offering Costs $112.07K.
- 2021-03-31: Deferred Offering Costs $138.93K.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-03-31 | $25.00K 10-Q · filed 2025-05-12 |
| 2024-06-30 | $106.30K S-4 · filed 2026-07-02 |
| 2021-06-30 | $112.07K 10-K · filed 2021-09-24 |
| 2021-03-31 | $138.93K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $328.85K 10-Q · filed 2021-02-11 |
| 2020-09-30 | $128.91K 10-Q · filed 2020-12-17 |
| 2020-06-30 | $290.69K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |